Ulrike Pötschger

6PUBLICATIONS
80CO-AUTHORS
Haematological tumoursImmunogenetics (incl. genetic immunology)Probability theoryCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 08, 2025
Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial.

Holger N Lode, Nikolai Siebert, Dominique Valteau-Couanet

|Feb 28, 2023
Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial.

Tim Flaadt, Ruth L Ladenstein, Martin Ebinger

|Sep 09, 2022
Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study.

Paul G Kemps, Timo C E Zondag, Helga B Arnardóttir

|Nov 23, 2021
Weighted pseudo-values for partly unobserved group membership in paediatric stem cell transplantation studies.

Martina Mittlböck, Ulrike Pötschger, Harald Heinzl

|Jun 21, 2021
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study.

Alberto Garaventa, Ulrike Poetschger, Dominique Valteau-Couanet

|Jun 11, 2021
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).

Angela Bellini, Ulrike Pötschger, Virginie Bernard

Pageof 1

Frequent Collaborators

4 joint publications

Ruth Lydia Ladenstein

3 joint publications

Peter F Ambros

2 joint publications

Victoria Castel

2 joint publications

Maja Popovic-Beck